Introduction {#s1}
============

As a worldwide health problem, arsenic exposure is associated with numerous human diseases, including diabetes, neurological disorders, dermal diseases, and various types of cancer ([@c42]). The relationship between arsenic exposure and cardiovascular diseases (CVDs) has been highly analyzed, and accumulating evidence indicates that arsenic exposure is associated with the increased morbidity and mortality of multiple CVDs, including coronary heart disease, stroke, and atherosclerosis ([@c43]; [@c56]; [@c60]). For example, a prospective cohort study on 11,746 participants in Bangladesh demonstrated that arsenic exposure was adversely associated with CVD mortality ([@c12]). Several mechanisms have been proposed to explain arsenic-induced CVDs. For example, several studies suggest that arsenic can promote the development of atherosclerosis by inducing oxidative stress, which promotes inflammatory responses and perturbs endothelial nitric oxide homeostasis ([@c57]). Liver X receptor/retinoid X receptor (LXR/RXR) signaling can be activated by endogenous ligands, including oxysterols ([@c40]) and 9-*cis*-retinoic acid ([@c73]), to regulate the transcription of numerous genes. Many downstream genes, such as sterol regulatory element-binding protein 1 (*Srebp1c*), ATP binding cassette subfamily A member 1 (*Abca1*), ATP binding cassette subfamily G member 1/5/8 (*Abcg1/5/8*), cluster of differentiation 36 (*Cd36*), and cytochrome P450 family 7 subfamily A member 1 (*Cyp7a1*), play critical roles in cholesterol synthesis, metabolism, and efflux; therefore, members of the LXR/RXR signaling cascade are regarded as cholesterol sensors that control cholesterol levels in tissues ([@c75]). In addition, the LXR/RXR signaling axis also influences lipid homeostasis by regulating the expression of related genes ([@c68]). For example, previous studies found LXRs can activate the transcription of multiple lipogenic genes like *Srebp1c* and fatty acid synthase (*Fasn*) ([@c49]; [@c48]; [@c29]), and consistently, in livers of LXR-deficient mice, these genes have low expression levels ([@c48]; [@c49]). Moreover, a previous study demonstrated that a synthetic LXR ligand reduced atherosclerotic lesions in two mouse models ([@c30]), suggesting that activation of the LXR/RXR pathway may attenuate atherosclerosis, and by extension, that the LXR/RXR signaling may play a role in the development of CVDs in general. Recent studies revealed that the LXR/RXR signaling pathway was inhibited by arsenic exposure ([@c46]), which was directly associated with arsenic-induced atherosclerosis in an apolipoprotein E knockout ($ApoE^{- / -}$) mouse model ([@c35]). Previous studies have shown that arsenic exposure inhibits the expression of genes downstream of the LXR/RXR signaling pathway, such as *Abca1* and *Srebp1c* ([@c36]; [@c46]), and $\text{LXR}\alpha$ knockout prevents arsenic-enhanced atherosclerosis in $ApoE^{- / -}$ mice ([@c35]). These findings suggested that perturbation of the LXR/RXR signaling axis potentially represents an important mechanism underlying the cardiovascular effects of arsenic.

The gut microbiota is deeply involved in numerous host physiological processes, such as food digestion, immune system development, and xenobiotic biotransformation ([@c28]; [@c44]), and also plays an important role in the development of CVDs. For example, the gut microbiota--produced trimethylamine (TMA) can be oxidized to TMA oxide ([@c2]; [@c51]), which enhanced macrophage cholesterol accumulation ([@c70]) and induced the development of atherosclerotic plaques ([@c34]) in mouse models. Moreover, gut microbiota--stimulated inflammation can modulate host gene expression to affect lipid and cholesterol homeostasis, which increases the risk of atherosclerosis ([@c10]). Recently, studies have shown that complex interactions exist between arsenic exposure and the gut microbiota. On the one hand, arsenic exposure can perturb the normal gut microbiota community and alter its metabolic pattern ([@c15]; [@c37]); on the other hand, the gut microbiota also influences arsenic biotransformation and its toxic effects ([@c16]; [@c38]; [@c52]). However, whether the gut microbiota influences arsenic-induced LXR/RXR inhibition and cholesterol/lipid dysbiosis remains unknown. In this study, we treated mice with antibiotics to generate a mouse model with the gut microbiota being largely reduced or depleted, and compared the effects of arsenic exposure on LXR/RXR signaling and cholesterol and lipid homeostasis in conventional mice and mice treated with antibiotics.

Methods {#s2}
=======

Animals, Gut Microbiota Depletion, Arsenic Exposure, and Sample Collection {#s2.1}
--------------------------------------------------------------------------

Sodium arsenite was obtained from Fisher Scientific, and 60 C57BL/6 female mice (specific pathogen-free grade, approximately 7 wk old) were purchased from Jackson Laboratories. All mice were maintained at the University of North Carolina animal facility in static microisolator cages with Bed-O-Cob (The Andersons Inc., Maumee, OH) combination bedding under standard environmental conditions (22°C, 40--70% humidity, and a 12:12-h light: dark cycle). Before the experiment began, the mice were observed for 1 wk at the animal facility. [Figure 1A](#f1){ref-type="fig"} shows the workflow of this study. Briefly, 30 mice were each treated with either antibiotics \[cefoperazone ($0.5\;{mg}/{mL}$); Sigma-Aldrich\] via drinking or clean drinking water for 72 h before arsenic exposure to generate the gut microbiota--depleted mouse model (AB-treated mouse) ([@c3]; [@c65]) and conventional mouse control groups, respectively. Then, mice were divided into six groups (10 mice each) as follows: Group \#A: conventional mouse control group; Group \#B: conventional mice exposed to $0.25\text{ \ ppm}$ arsenic for 2 wk via their drinking water; Group \#C: conventional mice exposed to $1\text{ \ ppm}$ arsenic for 2 wk via their drinking water; Group \#D: AB-treated mouse control group; Group \#E: AB-treated mice exposed to $0.25\text{ \ ppm}$ arsenic for 2 wk via their drinking water; and Group \#F: AB-treated mice exposed to $1\text{ \ ppm}$ arsenic for 2 wk via their drinking water. The $0.25\text{ \ ppm}$ arsenic is a relevant human dose level, and some arsenic-contaminated areas were reported that contained $0.25\text{ \ ppm}$ or higher levels of arsenic in the water, such as Bangladesh ([@c18]), India ([@c58]), and Vietnam ([@c9]), and $1\text{ \ ppm}$ arsenic also can be found in the groundwater in some severely contaminated areas ([@c9]). Both $0.25\text{-ppm}$ and $1\text{-ppm}$ dose levels have been widely adopted by previous studies ([@c19]; [@c27]; [@c61]). Standard pelleted rodent diet and sterilized tap water were provided to the mice *ad libitum*. Drinking water was refreshed twice a week, and weekly water consumption of each cage (five mice per cage) was monitored (Table S2). The antibiotics were administered to AB-treated mice throughout the arsenic exposure to maintain the gut microbiota depletion condition. After 2 wk of arsenic exposure, the mice were euthanized with carbon dioxide and necropsied to collect their sera and livers. Heart blood were collected, put in blood collection tubes (BD Microtainer®; BD), and centrifuged at $10,000 \times g$ at room temperature for 1 min after 1 to 2 h. Then, sera (the upper layer) were collected and stored in $- 80{^\circ}C$ until use. Half of each liver was placed in liquid nitrogen, and the other half was treated with RNA*later* (Thermo Fisher Scientific) for gene expression analysis. All samples were stored at $- 80{^\circ}C$ until use. All mice were treated humanely, and the experimental protocol was approved by the University of North Carolina Animal Care Committee.

![The experimental workflow and RNA-Seq (transcriptome sequencing) pathways. (A) Experimental workflow. (B,C) The top canonical pathways altered by arsenic exposure in livers of conventional and antibiotic (AB)-treated mice, respectively ($n = 5/\text{group}$). Note: IL-1, interleukin 1; LPS, lipopolysaccharide; PXR, pregnane X receptor; RXR, retinoid X receptor.](ehp-127-097002-g0001){#f1}

Validation of Gut Microbiota Depletion by Antibiotics {#s2.2}
-----------------------------------------------------

After 72 h antibiotics treatment, we collected mouse fecal samples and extracted fecal DNA using a PowerSoil® DNA Isolation Kit (Qiagen) according to instructions of the manufacturer. A negative control was set by adding no fecal sample in each batch of DNA extraction. DNA samples were quantified by a NanoDrop spectrophotometer (Thermo Fisher Scientific), and then we amplified bacterial 16S ribosomal ribonucleic acid (rRNA) with universal primers (iTRU-A 515 F and iTRU-1 806 R) by polymerase chain reaction (PCR) on a C1000 Touch™ thermal cycler (Model 550; Bio-Rad) programmed as follows: 3 min at 95°C for initial denaturation and 18 cycles of 20 s at 95°C, an annealing step at 60 °C for 30 s, 30 s at 72°C for extension, and 5 min at 72°C for a final extension, as previously described ([@c37]). PCR products were loaded to a 1.5% agarose gel to perform gel electrophoresis, and the signal intensities were checked under ultraviolet (UV) light.

Liver RNA-Seq Library Preparation, Sequencing, and Data Analysis {#s2.3}
----------------------------------------------------------------

The RNeasy Mini Kit (Qiagen) was used to isolate RNA from the liver (conventional control, $0.25\text{ \ ppm}$ arsenic-treated conventional mice, AB-treated mice, and $0.25\text{ \ ppm}$ arsenic- and AB-treated mice) according to the manufacturer\'s instructions. The resulting RNA was then digested with a DNA-free™ DNA Removal Kit (Thermo Fisher Scientific) to remove genomic DNA contaminants. The RNA quality was assessed on an Agilent 4200 TapeStation (Agilent Technologies), and the RNA integrity number threshold was set to 8.5. The KAPA stranded mRNA-Seq (transcriptome sequencing) kit (Kapa Biosystems) was used to prepare the RNA-Seq library according to the manufacturer's protocol. The libraries were sequenced at the Georgia Genomics Facility using an Illumina NextSeq High Output Flow Cell, and approximately 10 million reads were generated for each sample. Sequencing data were uploaded to the galaxy server (<https://usegalaxy.org/>), HISAT2 (Galaxy Version 2.1.0+galaxy4) ([@c32]) was applied to align the results, and Cufflinks (Galaxy Version 2.2.1.2) and Cuffdiff (Galaxy Version 2.2.1.5) were applied to assemble the transcripts, estimate their abundances, and detect significant changes in transcript expression ([@c66]). The differential gene expression table were uploaded to Qiagen\'s Ingenuity® Pathway Analysis (IPA®; Qiagen) software for pathway analysis. The cutoff value for each gene was set as $q < 0.05$. Top canonical pathways (top five pathways with the smallest *p*-values) generated by IPA were analyzed, and *z*-scores were automatically calculated by IPA.

Quantitative Real-Time Polymerase Chain Reaction {#s2.4}
------------------------------------------------

The hepatic RNAs of all six groups of mice ($n = 8/\text{group}$) were extracted by the RNeasy Mini Kit (Qiagen) following the manufacturer\'s instructions. The digestion of potential contaminated genomic DNA was performed as described above. cDNA was synthesized using iScript™ Reverse Transcription Supermix (Bio-Rad Laboratories), and the sixfold diluted products were used for quantitative real-time PCR (qPCR). qPCR was performed on a Bio-Rad CFX96 Touch Real-Time PCR Detection System using SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad). The qPCR conditions were 95°C for 10 min, followed by 39 cycles of 15 s at 95°C, 30 s of annealing at primer-specific temperatures, and 30 s at 72°C, and a final melting curve analysis was performed by raising the temperature from 65--95°C in 0.5°C increments for 0.05 s each. The sequences of the primers (purchased from Integrated DNA Technologies) and their annealing temperatures used for qPCR are shown in Table S1. $\beta\text{-actin}$ was used as the endogenous control, and the relative expression of each gene was calculated using the $\Delta\Delta\text{CT}$ method with CFX (version 3.1) manager software (Bio-Rad). The No-RT control and No-template control were set to avoid potential genomic DNA contamination and other technical contaminants, which were run in exactly the same way as the experimental samples but replaced reverse transcriptase solution and templates with nonreverse transcriptase solution and water, respectively.

Liver and Serum Total Cholesterol Measurement {#s2.5}
---------------------------------------------

Liver and serum total cholesterol levels were measured using a cholesterol assay kit \[Cholesterol Assay Kit - high-density lipoprotein (HDL) and low-density lipoprotein (LDL)/very low-density lipoprotein (VLDL) (ab65390); Abcam\]. The colorimetric assay protocol was used, and the detection range was from 0 to $100\text{ \ ng}/\mu L$. All experimental procedures were performed according to the manufacturer's protocol.

Liver and Serum Lipid Extraction, Liquid Chromatography--Mass Spectrometry Measurement, and Data Analysis {#s2.6}
---------------------------------------------------------------------------------------------------------

Liver and serum lipid extraction was performed according to a previously described method with some modifications ([@c39]). Briefly, for serum, a $20\text{-}\mu L$ sample aliquot was placed in a $1.5\text{-}{mL}$ Eppendorf tube, $225\;\mu L$ of cold methanol was added, and the sample was vortexed for 10 s. For the liver, $50\;{mg}$ sample was placed in a $1.5\text{-}{mL}$ Eppendorf tube containing 2.8-mm zirconium oxide beads, $225\;\mu L$ of cold methanol was added, and the sample was homogenized on a TissueLyzer (Qiagen, Hilden, German) at $50\text{ \ Hz}$ for 10 min. Then, for both liver and serum samples, $750\;\mu L$ of cold methyl tert-butyl ether was added, and the sample was shaken on an orbital mixer for 10 min. Next, $188\;\mu L$ of room-temperature liquid chromatography--mass spectrometry (LC-MS)--grade water was added, and the sample was vortexed for 20 s. The sample was centrifuged at $14,000 \times g$ for 2 min, and approximately $700\;\mu L$ of liquid was transferred from the top layer, dried in a SpeedVac (Thermo Fisher Scientific, Waltham, MA), and reconstituted in $65\;\mu L$ of methanol: chloroform (90:10, v/v) for instrumental analysis. The serum and liver lipids were analyzed on an Agilent 6530Accurate Mass Quadrupole Time-of-Flight (Q-TOF) LC/MS system (Agilent) in negative and positive modes with a full scan mode. The MS1 data files were uploaded to the XCMS online server (<https://xcmsonline.scripps.edu/>) to align the peaks and calculate the peak intensities. The ultra-performance liquid chromatography (UPLC)/Q-TOF parameter set was selected. The significantly changed features were selected ($q < 0.05$; $\text{intensity} > 1,000$), and METLIN ([@c53]) and LIPID MAPS (<https://www.lipidmaps.org/>) were used to annotate peaks (*m/z* accuracy was set to $10\text{ \ ppm}$).

Statistical Analysis {#s2.7}
--------------------

Differential gene expressions for RNA-Seq data were determined by Cuffdiff in galaxy, and $q < 0.05$ was set as the threshold. The two-way analysis of variance (ANOVA) in Prism 8 software (GraphPad) was applied to determine the statistical significance of gene expression differences measured by quantitative real-time reverse transcription PCR (qRT-PCR) and the different levels of hepatic and serum cholesterol. When two-way ANOVA reported the interaction *p*-value to be less than 0.05, Dunnett's multiple comparisons test was performed to determine how arsenic exposure changed the gene expression or cholesterol level. All adjusted *p*-values were calculated in Dunnett\'s multiple comparisons test in Prism 8 software. The specific calculating equations are as follows: $$MS{\,\left( \text{Error} \right)} = MS{\,\left( {\text{Subject} \times \text{Row\ factor}} \right)}$$$$\text{Mean\ diff} = \text{Mean}{\,\left( {\text{group}1} \right)} - \text{Mean}{\,\left( {\text{group}2} \right)}$$$$SE\text{ \ Difference} = \sqrt{MS{\,\left( \text{Error} \right)} \ast \left( {\frac{1}{N1} + \frac{1}{N2}} \right)}$$$$q = \frac{|\text{Mean\ diff}|}{SE\text{ \ Difference}}$$$$\text{Adjusted\  }p\text{-value} = \text{PFromQDunnet}\left( {q,\, DF,\, M} \right).$$where $N1$ and $N2$ are the sample sizes of $\text{group}1$ and $\text{group}2$, respectively; $MS{\,\left( \text{Error} \right)}$ is the appropriate mean square error; and $\text{Mean\ diff}$ is the mean difference between two groups.

An adjusted *p*-value (calculated by Prism 8 software) of less than 0.05 was considered a significant difference. For the LC-MS--based lipidomics, the featured differences between the two groups were determined by the unpaired parametric Welch's *t*-test, and the *q*-value threshold was set to 0.05.

Results {#s3}
=======

Effects of Antibiotics on Depleting Gut Bacteria and Water Consumption in Mice {#s3.1}
------------------------------------------------------------------------------

DNA quantities from the fecal samples of AB-treated mice were extremely low, as measured by a NanoDrop spectrophotometer, suggesting no significant amount of bacterial DNA could be extracted from AB-treated samples (fecal DNA concentration of conventional mice: $63.0 \pm 31.2\text{ \ ng}/\mu L$; fecal DNA concentration of AB-treated mice: $0.1 \pm 0.3\text{ \ ng}/\mu L$). Next, we used primers specific to the V4 region of bacterial 16S gene to amplify the sample for 18 cycles, followed by electrophoresis and visualization by UV light. No signal could be detected in the PCR products of AB-treated mice, while fecal samples from conventional mice had good 16S rRNA gene signals according the electrophoresis results (Figure S1). Therefore, these results demonstrated that antibiotics treatment significantly reduced or depleted gut bacteria in mice. In addition, we did not observe a water consumption difference between conventional mice and AB-treated mice (Table S2).

Effect of Arsenic Exposure on Hepatic Signaling Pathways in Conventional and Antibiotic-Treated Mice {#s3.2}
----------------------------------------------------------------------------------------------------

As a preliminary test to examine potential differential gene expressions, we first performed hepatic mRNA sequencing to compare the $0.25\text{ \ ppm}$ arsenic-induced differential gene expression in conventional and AB-treated mice, and we analyzed the disturbed metabolic pathways with IPA software. As shown in [Figure 1B,C](#f1){ref-type="fig"}, in the top canonical pathways (with the smallest *p*-values), the "LPS/IL-1 Mediated Inhibition of RXR Function" pathway was oppositely regulated by arsenic exposure in conventional and AB-treated mice. In addition, the enrichment of various RXR-related pathways was significantly perturbed in the $0.25\text{ \ ppm}$ arsenic-treated conventional mice, especially the LXR/RXR signaling pathway ([Figure 1B](#f1){ref-type="fig"}). Moreover, the cholesterol biosynthesis was one of the top five pathways perturbed by arsenic exposure in conventional mice but not in AB-treated mice ([Figure 1B,C](#f1){ref-type="fig"}; Tables S3 and S4). Likewise, the mRNA associated with the "Acute phase response signaling" and "Sirtuin signaling" pathways were in the top five pathways in AB-treated mice dosed with arsenic, but not in conventional mice. Major genes with differential expression levels between the two groups in each pathway are summarized in Tables S3 and S4.

Effects of Arsenic on the Expression of Downstream LXR/RXR Genes Associated with Cholesterol Metabolism and Efflux in Conventional and Antibiotic-Treated Mice {#s3.3}
--------------------------------------------------------------------------------------------------------------------------------------------------------------

Based on the RNA-Seq results, we hypothesized that arsenic exposure exerts different effects on hepatic LXR/RXR signaling as well as on cholesterol homeostasis in conventional and AB-treated mice. We applied qPCR to examine the expression of genes downstream of the LXR/RXR signaling pathway in livers of the two types of mice. Compared with the vehicle-treated mice, expression of multiple genes downstream of the LXR/RXR signaling pathway was significantly lower in both the $0.25\text{-ppm}$ and $1\text{-ppm}$ arsenic-exposed conventional mice groups, as were genes related to cholesterol homeostasis ([Figures 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}). First, genes associated with cholesterol synthesis and metabolism, including *Srebp1c* ([Figure 2A](#f2){ref-type="fig"}), 3-hydroxy-3-methylglutaryl-CoA reductase (*Hmgcr*) ([Figure 2B](#f2){ref-type="fig"}), and *Cyp7a1* ([Figure 2C](#f2){ref-type="fig"}), were expressed significantly less in arsenic-exposed conventional mice compared with controls. By contrast, in the AB-treated groups, the expression levels of *Hmgcr* (in mice treated with $1\text{ \ ppm}$ arsenic) and *Cyp7a1* (in mice treated with $0.25\text{ \ ppm}$ arsenic) were significantly higher than those in the AB-treated control group, while the expression of *Srebp1c* was not significantly different among the different treatment groups ([Figure 2](#f2){ref-type="fig"}). In addition, multiple cholesterol efflux-associated genes, including *Abcg5* ([Figure 3A](#f3){ref-type="fig"}), *Abcg8* ([Figure 3B](#f3){ref-type="fig"}), and *Cd36* ([Figure 3C](#f3){ref-type="fig"}), were also expressed at lower levels in arsenic-treated conventional mice than in the controls. However, none of the expression of these genes was significantly different in arsenic-exposed AB-treated animals compared with vehicle-exposed AB-treated animals ([Figure 3](#f3){ref-type="fig"}). Also, compared with controls, $1\text{ \ ppm}$ arsenic exposure resulted in moderately lower (adjusted $p < 0.1$) expression of *Abca1* in conventional mice, but significantly higher expression in AB-treated mice ([Figure 3D](#f3){ref-type="fig"}). Specific two-way ANOVA and multiple-comparison test results are shown in Tables S5 and S6.

![(A) Hepatic expression of sterol regulatory element-binding protein 1 (*Srebp1c*), (B) 3-hydroxy-3-methylglutaryl-CoA reductase (*Hmgcr*), and (C) cytochrome P450 family 7 subfamily A member 1 (*Cyp7a1*) in conventional and antibiotic (AB)-treated mice. Mice treated with either water or $0.5\;{mg}/{mL}$ cefoperazone were exposed to either vehicle, $0.25\text{ \ ppm}$ arsenic, or $1.0\text{ \ ppm}$ arsenic for 2 wk, after which mice were euthanized and liver tissues were harvested. Hepatic expression was evaluated using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Graphs show mean expression relative to endogenous control ($\beta\text{-actin}$) $+ \text{standard\ error\ of\ the\ mean\  }\left( \pm \text{SEM} \right)$. $n = 6–8$ per group. N.S., no significant difference ($p > 0.05$); \*$p < 0.05$; \*\*$p < 0.01$; \*\*\*$p < 0.001$. Adjusted *p*-values were determined by two-way analysis of variance (ANOVA) Dunnett's multiple comparisons test.](ehp-127-097002-g0002){#f2}

![(A) Hepatic expression of ATP binding cassette subfamily G member 5/8 (*Abcg*5), (B) *Abcg8*, (C) cluster of differentiation 36 (*Cd36*), and (D) ATP binding cassette subfamily A member 1 (*Abca1*) in conventional and antibiotic (AB)-treated mice. Mice treated with either water or $0.5\;{mg}/{mL}$ cefoperazone were exposed to either vehicle, $0.25\text{ \ ppm}$ arsenic, or $1.0\text{ \ ppm}$ arsenic for 2 wk, after which mice were euthanized and liver tissues were harvested. Hepatic expression was evaluated using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Graphs show mean expression relative to endogenous control ($\beta\text{-actin}$) $+ \text{ \ standard\ error\ of\ the\ mean\  }\left( \text{SEM} \right)$. $n = 6–8$ per group. N.S., no significant difference ($p > 0.05$); \*$p < 0.05$; \*\*$p < 0.01$; \*\*\*$p < 0.001$. Adjusted *p*-values were determined by two-way analysis of variance (ANOVA) Dunnett's multiple comparisons test.](ehp-127-097002-g0003){#f3}

Effects of Arsenic on the Expression of Downstream LXR/RXR Genes Associated with Markers of Reverse Cholesterol Transport in Conventional and Antibiotic-Treated Mice {#s3.4}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Genes associated with reverse cholesterol transport (RCT) were also differentially expressed in mice treated with antibiotics compared with those that were not. In conventional animals, hepatic expression of scavenger receptor class B member 1 (*Scarb1*) was significantly lower after treatment with arsenic than in controls ([Figure 4B](#f4){ref-type="fig"}). However, expression of both LDL receptor (*Ldlr*) and *Scarb1* was significantly higher in AB-treated mice exposed to $1\text{ \ ppm}$ arsenic than in AB-treated controls ([Figure 4A,B](#f4){ref-type="fig"}).

![(A) Hepatic expression of scavenger receptor class B member 1 (*Scarb1*) and (B) low-density lipoprotein receptor (*Ldlr*) in conventional and antibiotic (AB)-treated mice. Mice treated with either water or $0.5\;{mg}/{mL}$ cefoperazone were exposed to either vehicle, $0.25\text{ \ ppm}$ arsenic, or $1.0\text{ \ ppm}$ arsenic for 2 wk, after which mice were euthanized and liver tissues were harvested. Hepatic expression was evaluated using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Graphs show mean expression relative to endogenous control ($\beta\text{-actin}$) $+ \text{standard\ error\ of\ the\ mean\  }\left( \text{SEM} \right)$. $n = 6–8$ per group. N.S., no significant difference ($p > 0.05$); \*$p < 0.05$; \*\*\*$p < 0.001$. Adjusted *p*-values were determined by two-way analysis of variance (ANOVA) Dunnett's multiple comparisons test.](ehp-127-097002-g0004){#f4}

Serum and Hepatic Cholesterol Concentrations in Conventional and AB-Treated Mice Exposed to Arsenic {#s3.5}
---------------------------------------------------------------------------------------------------

To further validate our hypothesis, we measured the cholesterol concentrations in the serum and liver. As shown in [Figure 5A](#f5){ref-type="fig"}, the serum cholesterol concentrations in $1\text{ \ ppm}$ arsenic-exposed conventional mice were significantly higher than those in control mice. By contrast, in AB-treated mice, the serum cholesterol level was significantly lower after $1\text{ \ ppm}$ arsenic exposure ([Figure 5A](#f5){ref-type="fig"}). Furthermore, serum cholesterol levels in $0.25\text{ \ ppm}$ arsenic-exposed animals were not significantly different compared with vehicle-exposed animals, but we still observed that serum cholesterol concentrations in $0.25\text{ \ ppm}$ arsenic-exposed conventional mice were moderately higher (adjusted $p > 0.05$) than those in control mice, while they were moderately lower (adjusted $p > 0.05$) in $0.25\text{ \ ppm-treated}$ and AB-treated mice than in AB-treated mice ([Figure 5A](#f5){ref-type="fig"}). In addition, hepatic cholesterol levels in arsenic-exposed mice were not significantly different in either conventional mice or AB-treated mice compared with vehicle controls (adjusted $p > 0.05$; [Figure 5B](#f5){ref-type="fig"}).

![(A) Serum, and (B) hepatic cholesterol levels in conventional and antibiotic (AB)-treated mice. Mice treated with either water or $0.5\;{mg}/{mL}$ cefoperazone were exposed to either vehicle, $0.25\text{ \ ppm}$ arsenic, or $1.0\text{ \ ppm}$ arsenic for 2 wk, after which mice were euthanized and serum and liver tissues were harvested. Cholesterol levels were measured by a cholesterol assay kit. $n = 10$ per group. N.S., no significant difference ($p > 0.05$); \*$p < 0.05$. Adjusted *p*-values were determined by two-way analysis of variance (ANOVA) Dunnett's multiple comparisons test.](ehp-127-097002-g0005){#f5}

Serum and Hepatic Lipid Patterns in Conventional and Antibiotic-Treated Mice Exposed to Arsenic {#s3.6}
-----------------------------------------------------------------------------------------------

We next investigated whether the effects of arsenic exposure on lipid homeostasis differed between conventional and AB-treated mice, using the $1\text{-ppm}$ arsenic group as an example. [Figure 6](#f6){ref-type="fig"} shows the serum lipids significantly perturbed by arsenic exposure in conventional mice. Dramatically, the levels of numerous triglycerides (TGs) were significantly higher in arsenic-treated conventional mice than in controls. Moreover, the levels of multiple lipids in sera were higher in arsenic-treated conventional mice than in controls, including phosphatidylserine, phosphatidylglycerol (PG), phosphatidylethanolamine (PE), phosphatidic acid (PA), and diacylglycerol (DG). However, no lipid feature has significant difference between control and $1\text{-ppm}$ arsenic-treated mice under antibiotic treatment conditions.

![Histogram of serum lipid levels in conventional mice treated with vehicle or $1\text{ \ ppm}$ arsenic for 2 wk ($n = 8$ per group). For antibiotic (AB)-treated mice, no serum lipid has significant difference between controls and arsenic-treated mice. The scale was generated by autoscaling based on peak intensity. Note: Cer, ceramides; DG, diglyceride; lysoPE, lysophosphatidyl-ethanolamine; PA, phosphatidic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine; TG, triglyceride.](ehp-127-097002-g0006){#f6}

In the liver, similarly, we found that the level of numerous lipids in conventional mice were disturbed by $1\text{ \ ppm}$ of arsenic exposure ([Figure 7](#f7){ref-type="fig"}). The levels of many monoacylglycerols (MGs) were higher in arsenic-treated conventional mice than in controls, while the levels of most of the perturbed PAs, Pes, and PGs were lower. However, for AB-treated mice, we did not detect any hepatic lipid to have significant difference between controls and arsenic-treated mice.

![Histogram of hepatic lipid levels in conventional mice treated with vehicle or $1\text{ \ ppm}$ arsenic for 2 wk ($n = 8$ per group). For antibiotic (AB)-treated mice, no hepatic lipid has significant difference between controls and arsenic-treated mice. The scale was generated by autoscaling based on peak intensity. Cer, ceramides; DG, diglyceride; MG, monoacylglycerol; PA, phosphatidic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine; TG, triglyceride.](ehp-127-097002-g0007){#f7}

Discussion {#s4}
==========

In this study, we investigated the roles of the gut microbiota on the arsenic-induced down-regulation of LXR/RXR signaling. The LXR/RXR signaling axis plays a central regulatory role in numerous physiological processes and especially affects lipid and cholesterol homeostasis ([@c40]; [@c68]; [@c73]; [@c75]). Previous studies demonstrated that arsenic exposure affects the expression of genes downstream of the LXR/RXR signaling cascade. For example, arsenic exposure could reduce the LXR/RXR ligand-induced expression of *Abca1* and *Srebp1c* in macrophages ([@c46]). In addition, 5 wk of $0.1\text{ \ ppm}$ arsenic exposure inhibited the mouse hepatic expression of *Srebp1c* ([@c1]). Moreover, in the $ApoE^{- / -}$ mouse model, arsenic exposure increased atherosclerosis, potentially by inhibiting LXR/RXR target genes, and $\text{LXR}\alpha$ knockout attenuated the effects of arsenic on atherosclerosis ([@c36], [@c35]). In this study, we also found that arsenic exposure disturbed the LXR/RXR signaling axis ([Figure 1](#f1){ref-type="fig"}). The lower expression levels of multiple genes downstream of the LXR/RXR signaling cascade suggest that this pathway is inhibited by arsenic treatment ([Figures 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}). However, arsenic-induced LXR/RXR signaling inhibition was not observed in AB-treated mice, which suggests the important role of a normal gut microbiota in the effects of arsenic on hepatic LXR/RXR signaling.

Previous studies suggest that arsenic exposure influences cholesterol homeostasis. For example, an early study demonstrated that arsenic exposure can increase the total serum cholesterol levels in humans ([@c5]), and another study found that arsenic inhibited the LXR/RXR signaling pathway to decrease *Abca1* expression, which inhibited cholesterol efflux from human and murine macrophages ([@c46]). Here, we found that compared with vehicle, arsenic exposure resulted in lower expression of multiple genes related to cholesterol synthesis and metabolism in the liver, such as *Srebp1c, Hmgcr*, and *Cyp7a1* ([Figure 2](#f2){ref-type="fig"}), and the liver is the main location in which cholesterol synthesis occurs. As a transcription factor, *Srebp1c* can be induced by LXR/RXR signaling to induce the transcription of genes associated with fatty acid and cholesterol synthesis ([@c49]; [@c55]). In addition, *Hmgcr* encodes the rate-limiting enzyme in cholesterol synthesis pathways, and *Cyp7a1* encodes the rate-limiting enzyme of bile acid synthesis ([@c17]; [@c47]; [@c54]). Therefore, arsenic-decreased expression of these genes should disturb cholesterol homeostasis. However, despite the lower expression of cholesterol synthesis genes, the concentration of hepatic cholesterol in arsenic-exposed animals was not significantly different ([Figure 5B](#f5){ref-type="fig"}). This result could partially be due to the lower expression of *Cyp7a1*, which reduces the cholesterol conversion to bile acids ([Figure 2A](#f2){ref-type="fig"}). In addition, the low expression of *Abcg5* and *Abcg8* might also compensate for the decrease in cholesterol synthesis ([Figure 3](#f3){ref-type="fig"}), since they effluxed cholesterol from the liver to peripheral tissues ([@c4]; [@c74]). By contrast, the expression of these genes in arsenic-exposed mice treated with antibiotics was often not significantly different from control or, in some cases, was significantly different, but in a direction opposite that of the conventional mice ([Figures 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}). These data suggest that the reduction or depletion of the gut microbiota by antibiotics protects the host from arsenic-induced inhibition of cholesterol synthesis, metabolism, and efflux, highlighting the role of gut microbiota as an important mediator of arsenic effects on cholesterol homeostasis.

In addition, serum cholesterol levels were significantly higher in $1\text{ \ ppm}$ arsenic-treated conventional mice ([Figure 5A](#f5){ref-type="fig"}) than in controls. Since genes associated with cholesterol synthesis had low expression levels, the high levels of serum cholesterol should have mainly been caused by the relative low expression of *Ldlr* and *Scarb1* ([Figure 4A](#f4){ref-type="fig"}). LDLR, encoded by the *Ldlr* gene, is the receptor for LDL ([@c23]), and SR-B1, encoded by the *Scarb1* gene, is the receptor for HDL ([@c67]). LDLR and SR-B1 conduct RCT, during which cholesterol is removed from circulation, and thus play important roles in cholesterol homeostasis ([@c45]; [@c64]). Conversely, AB-treated mice exposed to $1\text{ \ ppm}$ arsenic had significantly lower serum cholesterol levels than the controls, which was consistent with the high expression levels of *Ldlr* and *Scarb1* ([Figures 4B](#f4){ref-type="fig"} and [5B](#f5){ref-type="fig"}). High serum cholesterol levels are considered a risk factor for CVDs, as they are associated with high CVD morbidity and mortality rates ([@c59]). Therefore, our data indicate that the effects of arsenic exposure on cholesterol homeostasis can be profoundly modified by the status of the gut microbiota, which may further influence disease outcomes due to exposure to arsenic and beyond.

In addition to the homeostasis of cholesterol, arsenic also influences lipid and fatty acid metabolism. According to previous studies, chronic arsenic exposure could disrupt lipid metabolism ([@c13]) and improve TG levels in rat serum when coapplied with a high-cholesterol diet ([@c71]). In addition, arsenic exposure can induce lipid accumulation in macrophages in an $ApoE^{- / -}$ mouse model ([@c35]). Herein, our study also indicated that both serum and liver lipid homeostasis were largely perturbed in conventional mice exposed to $1\text{ \ ppm}$ arsenic ([Figures 6](#f6){ref-type="fig"} and [7](#f7){ref-type="fig"}). We found that the levels of multiple types of serum lipids were higher in $1\text{ \ ppm}$ arsenic-exposed mice than in control mice ([Figure 6](#f6){ref-type="fig"}). The level of TGs was considerably higher ([Figure 6](#f6){ref-type="fig"}). Because the serum TG level is regarded as a risk factor for CVDs, the high TG level may indicate that arsenic increases the risk of CVDs ([@c26]). However, this effect was not observed in arsenic-exposed AB-treated mice, which, again, highlights the important role of the gut microbiota in the effects of arsenic exposure. Previous studies have revealed that the gut microbiota plays an important role in host lipid metabolism. For example, a previous study found bacteria-produced short-chain fatty acids played an important regulatory role in the balance among fatty acid synthesis, fatty acid oxidation, and lipolysis in the host body ([@c20]). A germ-free mouse had a different lipid/fatty acid pattern in its liver, serum, and adipose tissue than a conventional mouse ([@c69]). Another study also demonstrated that individual variations in the gut microbiota contribute to the differing blood lipid levels in humans ([@c21]). Thus, taken together, these previous studies and the study presented herein indicate that the status of the gut microbiota can profoundly modulate the effects of arsenic on lipid homeostasis.

This study provides evidence, based on an AB-treated mouse model, that the gut microbiota might attenuate or possibly reverse arsenic-induced LXR/RXR signaling inhibition and lipid/cholesterol dysbiosis. While the mechanism underlying these phenomena remain unclear, the data presented herein provide clues to how the gut microbiota influences the effects of arsenic on LXR/RXR signaling in the liver. First, gut microbiota--induced inflammation may play a key role in this process. A previous study showed that lipopolysaccharide (LPS) rapidly inhibited RXR proteins in the hamster liver ([@c8]). In addition, microbiota-induced intestinal inflammation can induce a retinoic acid deficiency, which may also influence the activation of RXR, since 9-*cis*-retinoic acid is an important endogenous ligand of RXR ([@c25]). Consistent with these studies, we also found that the "LPS/IL-1 Mediated Inhibition of RXR Function" pathway was activated in arsenic-exposed conventional mice, whereas this pathway, as well as the "Acute Phase Response Signaling" pathway, was inhibited in mice treated with antibiotics ([Figure 1B,C](#f1){ref-type="fig"}). Therefore, RXR inhibition could be a potential mechanism by which the gut microbiota affects arsenic-induced LXR/RXR inhibition. If this is true, we speculate that the gut microbiota-associated RXR inhibition would have impacts beyond LXR/RXR signaling, since RXR is required for multiple transcription factors, such as farnesoid X--activated receptor (FXR) ([@c24]), peroxisome proliferator--activated receptor alpha ([@c6]), thyroid hormone receptor (TR) ([@c11]), pregnane X receptor (PXR) ([@c33]), and constitutive androstane receptor ([@c62]). Indeed, we found that the gene expression--associated various related pathways were different between arsenic-treated conventional animals and control mice, including "PXR/RXR activation" and "TR/RXR Activation" ([Figure 1B](#f1){ref-type="fig"}). Second, bile acid conversion is a main source of cholesterol consumption, and bile acid--regulated FXR/RXR signaling also deeply influences LXR/RXR function as well as lipid and cholesterol homeostasis in the liver ([@c31]; [@c72]). Moreover, the gut microbiota is known to play a critical role in bile acid metabolism, and previous research revealed that the bile acid homeostasis in germ-free animals was largely different from those in conventional animals ([@c50]; [@c63]). Thus, it is possible that the gut microbiota mediates arsenic-induced lipid/cholesterol dysbiosis by mediating bile acid metabolism, thus influencing hepatic FXR/RXR signaling. Indeed, we also found that the gene encoding the rate-limiting enzyme CYP7A1 in bile acid synthesis was lower in arsenic-exposed conventional animals but higher in AB-treated mice exposed to arsenic ([Figure 2C](#f2){ref-type="fig"}). On the other hand, our previous studies revealed that arsenic exposure can dramatically reshape the gut microbiota community and its metabolic functions ([@c15]; [@c37]), thereby raising another possibility that arsenic exposure also influences bile acid homeostasis by disturbing the normal gut microbiota, resulting in lipid and cholesterol dysbiosis. However, our current understanding of the effect of arsenic exposure on bile acid homeostasis and whether the gut microbiota plays a role in this effect is still limited and needs to be explored in the future.

Our current study has several limitations. First, as a proof of principle study, to ensure the AB-treated mice were maintained in a good gut microbiota--depleting condition, we performed the 2-wk arsenic treatment, which is an acute exposure. However, arsenic exposure in humans is generally chronic. Therefore, how chronic arsenic exposure affects hepatic LXR/RXR signaling and whether gut microbiota plays a regulating role in this process still need to be further explored. Second, although we used environmentally relevant dose levels in this study, considering the relatively short exposure period and the mouse model we used, which requires a higher dose to reach the human-equivalent dose in the body ([@c41]), some of our analysis included both $0.25\text{ \ ppm}$ and $1\text{ \ ppm}$ exposure groups. Future study is warranted to explore the effects of arsenic exposure at more human-relevant low doses below $0.1\text{ \ ppm}$. Third, this study only used female mice, mainly because it has been well established in our previous studies that arsenic disrupted the normal gut microbiota compositions and their metabolic profiles in female mice, as well as their interactions with the host. However, sex is a critical factor in arsenic susceptibility ([@c7]), and our previous study found that arsenic and other environmental chemicals differently perturbed gut microbiota in female and male mice ([@c14]; [@c22]). Future studies are needed to elucidate the role of sex in exposure--microbiota--host interactions. Finally, gut microbiota has complex and far-reaching roles that affect numerous physiological processes in host bodies. We used antibiotics to treat mice, trying to generate mice with depleted gut microbiota. Our data show arsenic differentially altered lipid and cholesterol homeostasis in controls and mice treated with antibiotics, suggesting the potential role of the gut microbiota in these processes. However, the complicated effects of antibiotic treatment on host bodies could not be completely ruled out and need to be addressed in the future.

In conclusion, this study provides evidence in an AB-treated mouse model that the status of the gut microbiota can modify the effects of arsenic exposure on cholesterol and lipid homeostasis ([Figure 8](#f8){ref-type="fig"}). Arsenic exposure suppressed the expression of multiple genes involved in cholesterol synthesis, metabolism, and transportation in conventional mice but not in AB-treated mice. Moreover, serum cholesterol concentrations were oppositely regulated by arsenic in mice depending on the gut microbiota. The influence of arsenic exposure on liver and serum lipid homeostasis was also much smaller in AB-treated mice than in conventional mice. Our findings elucidate a new factor underlying the effects of arsenic on cholesterol and lipid metabolism and suggest that arsenic-induced cardiovascular effects may be attenuated by modulating the gut microbiota.

![A proposed diagram shows how gut microbiota affected the arsenic effects on liver X receptor/retinoid X receptor (LXR/RXR) pathways. The gut microbiota status affected the effects of arsenic on hepatic LXR/RXR signaling and thus might further affect lipid and cholesterol homeostasis. In mice with the normal gut microbiota, arsenic exposure inhibited the LXR/RXR signaling in the liver; disturbed the cholesterol synthesis, efflux, and absorption; and also affected the lipid homeostasis in liver and circulation. However, gut microbiota disruption attenuated or even reversed the effects of arsenic exposure on hepatic LXR/RXR signaling as well as the lipid and cholesterol homeostasis. *ABCG5/8*, ATP binding cassette subfamily G member 5/8; *CYP7A1*, cytochrome P450 family 7 subfamily A member 1; GI, gastrointestinal tract; HDL, high-density lipoprotein; *HMGCR*, 3-hydroxy-3-methylglutaryl-CoA reductase; LDL, low-density lipoprotein; *LDLR*, low-density lipoprotein receptor; *SRB1*, scavenger receptor class B member 1; *SREBP-1c*, sterol regulatory element-binding protein 1.](ehp-127-097002-g0008){#f8}
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